Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2012, Article ID 702910, 3 pages
Case Report

Refractory Clostridium difficile Infection Successfully Treated with Tigecycline, Rifaximin, and Vancomycin

1St. Matthew’s School of Medicine, USA
2Veterans Affairs New Jersey Healthcare System (VA NJHCS), East Orange, NJ 07018, USA
3Department of Infectious Disease, Appalachian Regional Hospital, Beckley, WV 25801, USA

Received 15 May 2012; Accepted 19 June 2012

Academic Editor: R. Coimbra

Copyright © 2012 Dominador Lao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The occurrence of Clostridium difficile colitis is on the rise and has become more difficult to manage with standard therapy. Thus, the need for alternative treatments is essential. Tigecycline is a glycylcycline antibiotic that has been shown to be effective against C. difficile through several published case reports and in in vitro studies. We present a case of C. difficile colitis that failed to respond to metronidazole and oral vancomycin therapy, but improved on a combination of rifaximin, tigecycline, and vancomycin.